Skip to main content
. 2021 Dec 17;23(2):51. doi: 10.3892/ol.2021.13169

Figure 4.

Figure 4.

FLT3 inhibitor (quizartinib and gilteritinib) treatment suppresses CD155 and CD112 surface expression in acute myeloid leukemia cell lines with FLT3 mutations. Histograms of CD155 and CD112 expression in MOLM-13 and MV-4-11 cells treated with quizartinib or gilteritinib (1 and 10 nM: yellow and green, respectively)/DMSO (red) for 48 h. FLT3, FMS-like tyrosine kinase 3; MFI, mean fluorescence intensity.